X4 PHARMACEUTICALS, INC Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
X4 PHARMACEUTICALS, INC (XFOR) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $2.56 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-03-17
- X4 PHARMACEUTICALS, INC effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $2.56M.
- X4 PHARMACEUTICALS, INC effective income tax rate reconciliation, tax credit, research, amount for fiscal 2018 was $0.00.
- X4 PHARMACEUTICALS, INC effective income tax rate reconciliation, tax credit, research, amount for fiscal 2017 was $0.00.
- X4 PHARMACEUTICALS, INC effective income tax rate reconciliation, tax credit, research, amount for fiscal 2016 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month |
|---|---|
| 2025-12-31 | $2.56M 10-K · filed 2026-03-17 |
| 2018-12-31 | $0.00 10-K · filed 2019-03-11 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-11 |
| 2016-12-31 | $0.00 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |